This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Sep 2011

Sucampo & Numab Enter into Discovery Collaboration for Antibodies

Sucampo Pharmaceuticals signs an R&D collaboration deal with Numab for the discovery of antibodies using the latter's high-affinity antibody technology.

US-based Sucampo Pharmaceuticals announced that its Swiss subsidiary, Sucampo AG, has formed a research and development collaboration with Swiss biotech company Numab. 


The agreement provides Sucampo with access to Numab’s proprietary technology for the discovery of high-affinity antibodies against certain selected targets. Sucampo will have exclusive commercial rights to any biologic products successfully developed and commercialised in the course of the collaboration.


Numab possesses a breakthrough antibody discovery technology that has been deliberately designed to approach complex integral membrane proteins such as GPCRs or ion channels, both major drug target classes that are not amenable to

Related News